NeuroWave CE marks brain monitor for anaesthetised patients
This article was originally published in Clinica
Executive Summary
Start-up company NeuroWave Systems has CE marked its lead product, the NeuroSense brain monitor, for sale in Europe. The device measures the brain function of patients undergoing general anaesthesia or sedation, which could improve patient outcomes and safety, the firm believes. For example, anaesthesia can increase the risk of stroke, which can be detected by the monitor. NeuroSense measures electroencephalogram (EEG) signals from both hemispheres of the brain, providing real-time feedback. NeuroWave (Cleveland Heights, Ohio) hopes that brain function monitoring during anaesthesia will become the standard of care in future, and is also pursuing US FDA approval. The market is currently worth $1bn per year and growing, it estimated.